explore -WSS

explore

author：fashion 2025-09-30 08:45:47 - browse：77818

Cambridge: AbbVie — Ruby Wallau for STAT

AbbVie will pay $10 billion for the biotech firm Immunogen, the company said Thursday, acquiring an approved treatment for ovarian cancer and buying into a burgeoning area of oncology.

Under the agreement, AbbVie will pay $31.26 per share in cash for Immunogen, a nearly 100% premium to the company’s recent trading price. Central to the deal, expected to close in the middle of next year, is Elahere, an Immunogen product that won Food and Drug Administration approval for advanced ovarian cancer in 2022.

Elahere is among a surging class of cancer medicines called antibody-drug conjugates, or ADCs, which are designed to deliver a targeted dose of chemotherapy directly to tumor cells while sparing healthy tissues. AbbVie’s acquisition is the latest multibillion-dollar deal in the space, following Merck’s $22 billion agreement with ADC specialist Daiichi Sankyo and Pfizer’s $43 billion buyout of Seagen earlier this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Novo: Oral version of Ozempic leads to 15% weight loss

hotspot

WSS

Telehealth options flood the market as retailers push virtual care

Timeline: Key moments in fight for gay rights

Novo: Oral version of Ozempic leads to 15% weight loss

Correcting Robert F. Kennedy Jr.'s vaccine 'facts'

Readout Newsletter: The latest from Bristol, Sarepta, and Novartis

Traditional Chinese medicine benefits explored in new JAMA study

Wikipedia

explore

focus

Supreme Court strikes down use of affirmative action

Reanimated hearts work just as well for transplants, study finds

Wildfire smoke exposes gaps in outdoor worker protections

Altering the blood type of lungs raises potential for universal organs for transplants

Medical leaders decry Supreme Court decision on affirmative action

Physician subsidies by hospitals soar in wake of No Surprises Act

Drug repurposing or repositioning? The language matters

Maker of FluMist seeks to allow at

After affirmative action ruling, medical educators look to 'holistic review'

Telehealth options flood the market as retailers push virtual care

focus

Meta's Zuckerberg and Chan on track to put $50 billion into science

Telehealth options flood the market as retailers push virtual care

Why Sanofi got shellacked over its spinoff

FDA approves first new drug developed for postpartum depression

Inside the rise of 'mukbang' eating videos

Biogen nominates mother of director’s child to replace him on board

explore

focus

hotspot

leisure time